Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) just unveiled an announcement.
On February 4, 2026, Qiagen reported unaudited results for the fourth quarter and full year ended December 31, 2025, posting Q4 net sales of $540 million, up 4% year on year (1% at constant exchange rates), and diluted EPS of $0.49, with adjusted diluted EPS of $0.62 at constant exchange rates beating its guidance. For 2025, net sales rose 6% to $2.09 billion (5% at constant exchange rates), at the top end of its upgraded outlook, while adjusted diluted EPS reached $2.40 at constant exchange rates, ahead of forecasts, underpinned by 8% constant-currency growth in its strategic growth pillars to $1.49 billion, an 80-basis-point improvement in adjusted operating margin to 29.5% despite tariffs and FX headwinds, and the first contribution from the Parse acquisition alongside headwinds from discontinued NeuMoDx and Dialunox products. Management highlighted disciplined execution in a challenging macro environment, including the impact of the 2025 U.S. government shutdown, continued cost-efficiency and digitization efforts, and an accelerated capital allocation program that returned more than $1.1 billion to shareholders and added Genoox and Parse as bolt-on deals, while setting a 2026 outlook for at least 5% constant-currency sales growth driven by roughly 9% growth in its core pillars and adjusted EPS of at least $2.50, signaling confidence in sustained profitable expansion and ongoing investment capacity.
The most recent analyst rating on (QGEN) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
Spark’s Take on QGEN Stock
According to Spark, TipRanks’ AI Analyst, QGEN is a Outperform.
The score is driven primarily by strong profitability and operating margins, supported by a positive and confidence-building earnings update (beat/raise and shareholder return actions). This is balanced by slower reported revenue growth and declining free cash flow growth, plus an overbought technical setup (RSI > 80) despite a clear uptrend.
To see Spark’s full report on QGEN stock, click here.
More about Qiagen
QIAGEN N.V., based in Venlo, the Netherlands, is a life sciences and molecular diagnostics company whose portfolio spans sample technologies, genomics/next-generation sequencing (NGS) and diagnostic solutions. Its business is organized around defined “growth pillars,” including sample technologies and digital and bioinformatics offerings, with a significant share of revenues generated in currencies other than the U.S. dollar and a strategy focused on profitable growth, portfolio streamlining and bolt-on acquisitions to strengthen its competitive position.
Average Trading Volume: 1,916,743
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.69B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.